ArticleFrontiers in cardiovascular medicine2025
Efficacy and safety of leadless pacemaker implantation in octogenarians: a single-center experience.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pacing-Induced Cardiomyopathy in Leadless and Transvenous Pacemakers: A Meta-Analysis and Meta-Regression.Pacing and clinical electrophysiology : PACE · 2026Pooled it
- Sex and Age Differences in Procedural and Medium-Term Electrical Performance Outcomes of Dual-Chamber Leadless Pacemakers.Journal of cardiovascular electrophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Long-term complications occur in approximately 4%-12% of patients with standard transvenous pacemakers (TVPs), most of whom are elderly. The leadless pacemaker (LP) has emerged as an effective alternative to traditional TVPs, offering a lower complication profile. However, data on LP implantation in octogenarians remain limited, and concerns persist regarding its feasibility and safety in this population. This study aimed to assess the feasibility and clinical outcomes of LP implantation in octogenarians. Methods and Results: Between January 2021 and January 2024, 154 patients (mean age 75.5 ± 9.8 years) who underwent LP implantation at our center were consecutively included. The study cohort was stratified into two age groups: octogenarians (≥80 years, mean age 84.2 ± 3.3 years, Conclusions: LP implantation appears to be a safe and effective therapeutic option for octogenarians, including those with more combabilities. Therefore, it should be considered a viable alternative to conventional TVPs in this aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.